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Effect of Comorbidity On 
Unplanned Readmissions 
After Percutaneous Coronary 
Intervention (From The Nationwide 
Readmission Database)
Chun Shing Kwok  1,2, Sara C. Martinez3, Samir Pancholy4, Waqar Ahmed5,  
Khaled al-Shaibi5, Jessica Potts1, Mohamed Mohamed  1,2, Evangelos Kontopantelis  6, 
Nick Curzen7,8 & Mamas A. Mamas1,2
It is unclear how comorbidity influences rates and causes of unplanned readmissions following 
percutaneous coronary intervention (PCI). We analyzed patients in the Nationwide Readmission 
Database who were admitted to hospital between 2010 and 2014. The comorbidity burden as defined 
by the Charlson Comorbidity Index (CCI). Primary outcomes were 30-day readmission rates and causes 
of readmission according to comorbidity burden. A total of 2,294,346 PCI procedures were included the 
analysis. The patients in CCI = 0, 1, 2 and ≥3 were 842,272(36.7%), 701,476(30.6%), 347,537(15.1%) and 
403,061(17.6%), respectively. 219,227(9.6%) had an unplanned readmission within 30 days and rates by 
CCI group were 6.6%, 8.6%, 11.4% and 15.9% for CCI groups 0, 1, 2 and ≥3, respectively. The CCI score was 
also associated with greater cost (cost of index PCI for not readmitted vs readmitted was CCI = 0 $21,257 
vs $19,764 and CCI ≥ 3 $26,736 vs $27,723). Compared to patients with CCI = 0, greater CCI score was 
associated with greater independent odds of readmission (CCI = 1 OR 1.25(1.22–1.28), p < 0.001, CCI ≥ 3 
OR 2.08(2.03–2.14), p < 0.001). Rates of non-cardiac causes for readmissions increased with increasing 
CCI group from 49.4% in CCI = 0 to 57.1% in CCI ≥ 3. Rates of early unplanned readmission increase with 
greater comorbidity burden and non-cardiac readmissions are higher among more comorbid patients.
The average age of patients who undergo percutaneous coronary intervention (PCI) in western populations has 
increased over time, reflecting an increasingly elderly population who often have comorbid conditions in addition 
to their prevalent cardiovascular disease1,2. In a general population, it is reported that 42% of patients have one 
or more comorbidties and 23% were multimorbid with the prevalence of multimorbidity increased substantially 
with age3. At least 75% of patients undergoing PCI have at least 1 comorbid condition4. While technical advances, 
improvements in stent platforms, and pharmacology have enabled higher-risk elderly and comorbid patients to 
be treated with PCI5, comorbidity is increasingly recognized as an important prognostic factor in PCI4,6. Among 
patients who undergo PCI, comorbid conditions are typically considered as prevalent individual risk factors for 
cardiovascular disease, rather than a more holistic measure of comorbid burden where both cardiovascular and 
non-cardiovascular comorbidities may influence outcomes synergistically rather than in isolation.
The most commonly used measure of comorbid burden is the Charlson comorbidity index (CCI)4, derived 
from several comorbid conditions, that utilizes both the number and the impact of individual comorbidities in 
order to determine the prognosis of patients with a variety of medical conditions7. As a tool, it has been used to 
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estimate prognosis in patients with multiple coexisting illness with a broad range of cardiovascular diseases6. CCI 
has been shown to be an important independent predictor of adverse outcomes following PCI, with previous 
studies reporting an association between CCI and cardiac death, major adverse cardiovascular events, major 
bleeding, and stent thrombosis in the setting of PCI2,4,8.
Readmissions following PCI are an area of growing interest and contributory mechanisms are not well under-
stood9,10. To patients, readmission represents a burden emotionally and represents an adverse clinical outcome. 
Further, readmissions place a resource burden on healthcare provision. As such, readmissions serve as a surrogate 
for quality of care which can incur financial penalties for hospitals. Whilst comorbidity burden (as measured by 
CCI) has been shown to be predictive of unplanned readmission following emergency general surgery11, ortho-
paedic surgery12 and in general hospital readmissions13, previous work that has studied unplanned readmissions 
post-PCI has not considered whether there is an association between comorbid burden and the rates or causes 
of such readmissions. The objective of the current study is to evaluate the comorbidity burden as defined by the 
CCI and its impact on the rates and causes of 30-day unplanned readmissions after PCI in an unselected national 
cohort.
Results
A total of 2,294,346 procedural episodes in patients who survived index PCI were included in the analysis (Fig. 1). 
The prevalence of comorbidity in patients who undergo PCI has increased over time (Fig. 2). The proportion of 
patients with a CCI score of ≥3 increased from 15.8% in 2010 to 19.6% in 2014 while the proportion of patients 
with CCI score of 0 declined from 38.1% in 2010 to 35.2% in 2014. The number of patients with 30-day unplanned 
readmissions between 2010 and 2014 was 219,227 (9.6%). In CCI groups 0, 1, 2 and ≥3, there were a total of 
842,272, 701,476, 347,537 and 403,061 patients, respectively and the rates of unplanned readmissions were 6.6%, 
8.6%, 11.4% and 15.9% for the groups CCI = 0, 1, 2 and ≥3.
The trends in readmissions rates of patients according to comorbidity group are shown in Fig. 2. No major 
changes in readmissions rates were observed over time and the readmission rate for CCI ≥ 3 ranged between 
15.8% and 16.4%. The corresponding range for CCI = 0 declined over time from 7.1% to 5.9%.
The characteristics according to CCI group and readmission status is shown in Table 1. In all CCI groups, 
patients who were older (CCI = 0, 65 vs 62 years; CCI ≥ 3, 68 vs 67 years) and female (CCI = 0, 36.1% vs 27.1%; 
CCI ≥ 3 40.5% vs 36.3%) were significantly more likely to be readmitted. Patients who underwent an elective 
PCI procedure were less likely to be readmitted (11.5% vs 16.0% for CCI = 0 and 10.6% vs 16.2% for CCI ≥ 3). 
Readmitted patients were more likely to be on Medicare (CCI = 0 50.5% vs 40.2%, CCI ≥ 3 77.2% vs 73.0%), and 
there were fewer patients with private healthcare (CCI = 0 29.5% vs 40.7%, CCI ≥ 3 10.9% vs 15.2%). Alcohol 
misuse was not significantly different in those readmitted and not readmitted for patients with CCI ≥ 3 (2.5% 
vs 2.4%, p = 0.63) but significantly different for all other CCI categories. The vast majority of patients were dis-
charged home, but the rates of patients discharged to care homes increased with increasing CCI group. CCI score 
was also associated with greater cost as the hospital cost of index PCI for CCI = 0, 1, 2 and ≥ 3 for the readmitted 
compared to not readmitted group was $21,257 vs $19,764, $21,933 vs $20,558, $23,580 vs $22,741 and $26,736 
vs $27,723, respectively. Length of stay on index admission was greater for patients who were readmitted in CCI 
groups 0, 1 and 2 (3.5 vs 2.8 days, 3.9 vs 3.2 days and 4.6 vs 4.1 days, respectively.
Following adjustment for baseline covariates not already included in the CCI score, greater CCI score was 
associated with greater independent odds of readmission (CCI = 1 OR 1.25 95%CI 1.22–1.28, p < 0.001, CCI = 2 
OR 1.58 95%CI 1.53–1.62, p < 0.001, CCI ≥ 3 OR 2.08 95%CI 2.03–2.14, p < 0.001) compared to patients with 
CCI = 0, (Fig. 3). The causes of readmissions by CCI group are shown in Table 2 and Figs 4 and 5. Rates of 
non-cardiac causes for readmissions increased with increasing CCI group from 49.4% in CCI = 0 to 57.1% in 
CCI ≥ 3. For non-cardiac causes of readmission, increase in CCI score was associated with a higher prevalence 
Figure 1. Flow diagram of patients.
www.nature.com/scientificreports/
3SCiENTiFiC RepoRts |  (2018) 8:11156  | DOI:10.1038/s41598-018-29303-y
of readmission for respiratory diseases and a lower prevalence of readmission due to non-specific chest pain and 
gastrointestinal disease. For cardiac causes of readmission, a higher CCI score was associated with a higher prev-
alence of readmission for heart failure and arrhythmias and a lower prevalence of readmission related to coronary 
artery disease including angina and acute myocardial infarction. The cause of other non-cardiac readmissions is 
shown in Supplementary Table 2.
The outcomes for readmissions are shown in Table 3. The length of stay for the readmission was higher with 
greater CCI (CCI = 0 3.5 days, CCI = 1 3.9 days, CCI = 2 4.5 days, CCI ≥ 3 5.2 days, p < 0.001) as was the cost of 
the readmission (CCI = 0 $10,974, CCI = 1 $11,532, CCI = 2 $12,064, CCI ≥ 3 $13,177, p < 0.001). The mortality 
rates for the readmission increased with higher CCI score from 1.7% in CCI = 0 to 3.9% CCI ≥ 3 (p < 0.001).
Discussion
Comorbidity burden in patients who undergo PCI is associated with different rates of early unplanned readmis-
sions and is associated with prolonged length of stay in hospital, increased hospital cost, and greater mortality 
during the readmission episode. Our analysis shows that with increasing comorbid burden, there is an increase 
in non-cardiac causes for readmission. Finally, we show that causes of unplanned readmissions vary according 
to comorbid burden, with increasing comorbidity burden associated with a greater incidence of readmissions for 
respiratory causes, heart failure and arrhythmias, whilst patients with no significant comorbid burden were more 
likely to be readmitted with non-specific chest pain, gastrointestinal disease and manifestations of coronary artery 
disease such as angina.
Our data show that the comorbid burden of patients undergoing PCI has increased over time, but rates of 
readmission are consistently higher across all years at the highest comorbidity burden. While previous studies 
undertaken using national data have examined comorbidities in PCI, these studies have treated each comorbidity 
as an individual isolated factor rather than using global measures of comorbid burden, and have only considered 
comorbidities and adverse outcomes for the index PCI hospitalization14–17. To the best of our knowledge, this 
analysis is the first to report the relationship between global comorbid burden (made up of both cardiovascular 
and non-cardiovascular comorbidities) and unplanned hospital readmissions following PCI. For some patients, 
the risk of readmission may be greater as a direct consequence of their non-cardiac comorbidities rather than 
cardiac pathology or complications from the PCI procedure. The reasons for this are unclear. Comorbidities are 
complex because they can work independently or synergistically to modulate the propensity for patients to have 
readmissions related to cardiac disease, PCI related complications, and non-cardiac existing illnesses. Patients 
with comorbidities have an increased potential for adverse drug reactions18 and the liabilities of polypharmacy in 
Figure 2. Trends in comorbidity and readmission in patients with percutaneous coronary intervention.
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Age 62 ± 13 65 ± 14 <0.001 64 ± 12 66 ± 13 <0.001 67 ± 12 68 ± 13 <0.001 66.8 ± 12 68 ± 13 <0.001
Female 27.1% 36.1% <0.001 33.3% 41.4% <0.001 35.6% 42.0% <0.001 36.3% 40.5% <0.001
Year <0.001 <0.001 0.010 0.15
  2010 22.6% 24.5% 22.3% 22.9% 21.6% 21.6% 19.7% 19.7%
  2011 20.7% 21.9% 20.6% 21.3% 20.1% 21.1% 19.5% 20.1%
  2012 19.1% 18.8% 19.1% 19.5% 19.0% 19.0% 19.1% 18.9%
  2013 19.6% 18.8% 19.7% 19.3% 20.2% 19.3% 20.9% 20.7%
  2014 18.0% 16.0% 18.2% 17.0% 19.1% 19.0% 20.8% 20.5%
Elective admission 16.0% 11.5% <0.001 18.0% 11.8% <0.001 18.0% 11.5% <0.001 16.2% 10.6% <0.001
Weekend admission 21.3% 22.0% 0.007 19.6% 21.3% <0.001 19.7% 21.5% <0.001 20.1% 21.7% <0.001
Diagnosis of AMI 60.1% 58.4% <0.001 48.8% 50.3% <0.001 43.7% 45.9% <0.001 43.4% 47.1% <0.001
Primary expected payer <0.001 <0.001 <0.001 <0.001
  Medicare 40.2% 50.5% 49.7% 57.6% 61.9% 68.6% 73.0% 77.2%
  Medicaid 6.1% 8.4% 8.3% 10.5% 8.2% 9.7% 7.1% 8.1%
  Private 40.7% 29.5% 31.2% 22.1% 22.1% 15.4% 15.2% 10.9%
  Uninsured 7.7% 6.4% 6.1% 5.3% 3.9% 3.1% 2.0% 1.6%
  No charge 1.0% 1.1% 0.9% 0.9% 0.6% 0.4% 0.3% 0.2%
  Other 4.2% 4.0% 3.9% 3.6% 3.3% 2.7% 2.5% 2.0%
Median household income 
(percentile) <0.001 <0.001 0.001 0.013
0-25th 25.7% 27.0% 29.5% 31.4% 31.4% 32.4% 31.5% 32.4%
26-50th 24.7% 24.6% 25.6% 25.7% 25.8% 26.2% 25.3% 25.3%
51-75th 24.9% 24.5% 23.9% 23.4% 23.0% 22.7% 23.1% 22.9%
76-100th 24.7% 23.9% 21.0% 19.5% 19.9% 18.7% 20.1% 19.4%
Smoking 41.2% 37.5% <0.001 41.9% 40.1% <0.001 44.4% 42.4% <0.001 39.2% 38.1% 0.001
Alcohol misuse 2.8% 3.1% 0.003 2.5% 2.7% 0.035 2.6% 3.0% 0.005 2.4% 2.5% 0.63
Dyslipidemia 66.8% 63.4% <0.001 75.3% 70.6% <0.001 75.2% 70.3% <0.001 72.9% 69.0% <0.001
Hypertension 64.1% 66.9% <0.001 77.6% 77.5% 0.63 81.3% 81.1% 0.54 85.8% 86.0% 0.51
Bed size <0.001 <0.001 0.007 0.046
Small 6.2% 5.4% 5.7% 5.1% 5.4% 4.9% 4.9% 4.6%
Medium 21.1% 20.6% 20.5% 21.0% 20.4% 19.9% 20.3% 20.7%
Large 72.7% 74.0% 73.8% 73.9% 74.2% 75.2% 74.8% 74.7%
Location 0.26 0.26 0.054 0.17
Rural 0.2% 0.1% 0.2% 0.2% 0.2% 0.2% 0.3% 0.2%
Urban 99.8% 99.9% 99.8% 99.8% 99.8% 99.8% 99.8% 99.8%
Teaching status <0.001 0.002 <0.001 <0.001
Nonteaching 46.5% 47.7% 45.2% 46.3% 44.5% 46.2% 43.2% 44.9%
Teaching status 53.5% 52.3% 54.8% 53.7% 55.5% 53.8% 56.8% 55.1%
Multivessel disease 14.7% 15.1% 0.14 16.4% 15.8% 0.008 17.0% 16.5% 0.099 18.1% 17.7% 0.16
Bifurcation disease 2.8% 2.6% 0.074 2.8% 2.7% 0.38 3.0% 2.7% 0.048 3.1% 3.0% 0.19
Circulatory support 2.7% 4.9% <0.001 2.7% 4.1% <0.001 3.0% 3.7% <0.001 3.7% 3.9% 0.29
Vasopressor use 0.4% 0.6% <0.001 0.4% 0.5% <0.001 0.5% 0.6% 0.071% 0.6% 0.7% 0.40
IABP use 2.6% 4.6% <0.001 2.4% 3.7% <0.001 2.6% 3.2% <0.001 3.0% 3.2% 0.081
FFR use 1.7% 1.6% 0.61 1.9% 1.8% 0.34 2.1% 2.1% 0.78 2.2% 2.5% 0.005
IVUS use 6.9% 7.0% 0.52 7.0% 7.0% 0.90 7.2% 6.9% 0.20 7.2% 6.8% 0.016
DES 76.0% 69.6% <0.001 75.6% 69.7% <0.001 72.5% 67.4% <0.001 69.7% 66.0% <0.001
Complete heart block 0.9% 1.2% <0.001 0.9% 1.0% 0.33 1.0% 1.2% 0.010 1.3% 1.2% 0.83
Stroke or TIA 1.3% 1.9% <0.001 2.4% 2.7% 0.006 4.3% 4.3% 0.93 6.7% 6.0% <0.001
Cardiogenic shock 2.3% 4.0% <0.001 2.4% 1.7% <0.001 2.9% 3.8% <0.001 3.7% 3.9% 0.17
Cardiac arrest 1.9% 2.6% <0.001 1.4% 1.7% <0.001 1.6% 1.7% 0.26 2.1% 1.7% <0.001
Acute kidney injury 0.3% 0.6% <0.001 0.4% 0.8% <0.001 0.6% 1.1% <0.001 1.3% 1.4% 0.097
Bleeding 0.4% 0.7% <0.001 0.5% 0.9% <0.001 0.7% 1.1% <0.001 1.3% 1.5% 0.041
Blood transfusion 0.04% 0.08% 0.002 0.05% 0.10% <0.001 0.06% 0.07% 0.77 0.05% 0.08% 0.036
Vascular complication 0.6% 0.8% <0.001 0.7% 1.0% <0.001 1.0% 1.2% 0.001 1.2% 1.3% 0.035
Emergency CABG 1.2% 1.8% <0.001 1.4% 1.8% <0.001 1.6% 1.3% 0.011 1.3% 1.0% <0.001
Continued
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medication adherence19. In the current study, we have shown the CCI score, a measure of global comorbid burden 
is independently associated with increased cost, length of stay and readmission following PCI. This builds on our 
previous work which demonstrates that CCI was independently associated with cardiac death, major adverse 
cardiovascular events, major bleeding, and stent thrombosis in a much smaller multicentre registry of patients 
undergoing PCI4.
We show that differences in causes for readmission depend on the comorbidity burden in patients who 
undergo PCI. We observe that the prevalence of readmissions for infections and respiratory causes increase with 
greater comorbidity burden. Whilst it is not understood how chronic comorbid medical conditions influence 
risk of infections, there is evidence that certain diseases such as diabetes, chronic liver disease and cancer can 
increase the risk of sepsis20. In our current cohort, we found that the prevalence of chronic lung disease was high 
in the groups with comorbidity (CCI groups 1, 2 and ≥3 rates were 18%, 34% and 36% respectively). Chronic 
obstructive pulmonary disease is likely to represent a large population of the chronic lung disease in the current 
study and patients who have chronic obstructive pulmonary disease are known to have high rates of readmis-
sions (10%) within 30 days of COPD related admissions21. Prevalence of renal failure as a cause of readmission 
increased with greater CCI score to 5.6% with CCI ≥ 3.
Our results have several clinical implications. First, the patients with high comorbid burden are a high-risk 
group for readmissions. This suggests that patients with a high comorbidity burden should be assessed prior to 
discharge to ensure that their comorbidities are well-managed with appropriate follow up. To date, there has been 
one multimodal intervention which has been shown to reduce readmissions after PCI from 9.6% to 5.3%22. This 
intervention involves several measures including patient assessment with a validated risk score which contains 
3 comorbidities, discharge checklist, patient education video, follow-up clinic, and computerized notification 
system for attendance to emergency departments within 30 days. The discharge checklist advised instructions 
for managing heart failure, diabetes and other secondary diagnoses but did not specifically explain what these 
instructions were or how exactly to manage comorbidities. Secondly, assessment of comorbidity may be useful 
in predictive scores for readmissions. There are several published scores designed to predict readmission23,24, but 
only one which has been studied in a PCI population22. This contained the comorbidities chronic heart failure, 
chronic lung disease and peripheral artery disease but global comorbid burden was not considered, which maybe 
more important than these isolated comorbidities.
Our study has several strengths. First, this largest national study of patients who undergo PCI enables suffi-
cient sample size to consider the Charlson score and its relationship with readmissions. Secondly, the Nationwide 
Readmission Database is 99% complete for the variables in the current study. The data is designed to be 
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Discharge location <0.001 <0.001 <0.001 <0.001
Home (self-care) 94.2% 87.3% 91.2% 83.2% 85.2% 76.0% 74.3% 66.2%
Short term hospital 0.4% 0.8% 0.4% 0.6% 0.4% 0.7% 0.7% 0.8%
Transfer to other institution 1.6% 4.0% 2.7% 5.4% 5.4% 8.3% 10.7% 13.3%
Care home 3.4% 7.2% 5.3% 9.9% 8.5% 14.3% 13.9% 18.9%
Discharge against medical 
advice or discontinue care 0.4% 0.8% 0.4% 0.8% 0.4% 0.8% 0.4% 0.8%
Length of stay 2.8 ± 3.5 3.5 ± 3.1 <0.001 3.2 ± 4.2 3.9 ± 3.3 <0.001 4.1 ± 5.8 4.6 ± 3.9 <0.001 6.3 ± 8.6 6.0 ± 6.7 <0.001
Cost of index PCI $19,764 ± 14,066
$21,257 ±  
13,460 <0.001
$20,558 ±  
15,948
$21,933 ±  
13,622 <0.001
$22,741 ±  
19,409
$23,580 ±  
14,7044 <0.001




Table 1. Patient characteristics according to readmission status.
Figure 3. Adjusted odds of readmission by comorbidity.
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generalizable to hospitals in the United States rather than specific to a geographic area. Finally, we were able to 
consider the effect of a variety of patient characteristics, hospital-related, PCI-related and outcome-related varia-
bles and how they influence readmission rates.
Our study also has a few limitations. Firstly, there is no possible linkage between years as the data is derived 
from five unique datasets corresponding to each year between 2010 to 2014. We excluded patients who were 
discharged in the month of December in order to ensure adequate 30-day follow up. Another limitation was that 
the NRD dataset did not have data on completeness of revascularisation or procedural success and the use of 
discharge medications such as type and duration of dual antiplatelet therapy. Applicability of the data is extrapo-
lated to represent the country’s trends, as the collected data in the current analysis is derived from administrative 
claims from 21 states where regional heterogeneity could not be explored. In addition, we cannot exclude possible 
bias from coding errors, and we had to use the primary discharge diagnosis codes for causes of readmissions, 
which may be subject to bias. On the converse, we cannot know the true health status of all patients, as diagno-
ses exist when they are discovered. Arnold et al. demonstrated the rate of previously undiagnosed diabetes in 
patients presenting with AMI as 10%, although only 1/3 of those patients are identified, and only 5% of those with 
undiagnosed diabetes receive treatment at 6 months post discharge25. Although diabetes can be diagnosed easily 
with blood tests, other comorbid conditions such as COPD and occult malignancy may not present to clinical 
attention until the unplanned readmission. Finally, studies of readmissions may be affected by bias related to sur-
vivorship. Patients who died during the index PCI hospitalization are not considered and patients who died out 
of the hospital are not captured in the present analysis.
In conclusion, our results demonstrate that comorbidity is common in PCI and associated with early 
unplanned readmissions. The causes of readmissions are influenced by comorbidity where patients with higher 
comorbidity show a greater prevalence of non-cardiac causes for readmissions. These findings suggest that 
Figure 4. Cause of readmission by comorbidity group.
Top 10 non-cardiac causes of readmission CCI 0* CCI 1* CCI 2* CCI 3*
Non-specific chest pain 26.4% 21.6% 16.9% 10.4%
Gastrointestinal 13.1% 12.1% 10.8% 9.8%
Infections 8.2% 10.2% 12.7% 15.1%
Bleeding 6.2% 5.5% 5.5% 6.4%
Respiratory 5.1% 8.4% 10.0% 10.2%
TIA/stroke 5.0% 4.9% 4.7% 4.1%
Peripheral vascular disease 4.6% 4.4% 5.2% 4.5%
Genitourinary 2.9% 2.7% 2.6% 2.5%
Neuropsychiatric 2.9% 2.9% 2.6% 2.3%
Renal failure 1.8% 2.9% 4.1% 5.8%
Cardiac causes of readmission CCI 0** CCI 1** CCI 2** CCI 3**
Coronary artery disease including angina 45.5% 40.4% 33.1% 23.6%
Acute myocardial infarction 18.3% 18.0% 18.0% 17.8%
Heart failure 13.3% 18.5% 23.8% 33.4%
Arrhythmias 12.4% 12.1% 14.3% 16.2%
Pericarditis 1.6% 1.4% 1.1% 0.9%
Other cardiac 8.9% 9.6% 9.7% 8.2%
Table 2. Cause of readmission by comorbidity group. *% of non-cardiac cause of readmissions. **% of cardiac 
cause of readmissions.
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comorbidity should be considered in risk assessments for patients who undergo PCI and patient with high 
comorbid burden should be targeted for interventions which can reduce readmissions.
Methods
The Nationwide Readmissions Database (NRD) contains national hospitalization and rehospitalization data for 
patients of all ages within the United States, which is produced by the Healthcare Cost and Utilization Project of 
the Agency for Healthcare Research and Quality26. The data is derived from discharge-level data for hospitaliza-
tions from 21 geographically-dispersed states and is designed to represent 49.1% of all US hospitalizations9. The 
NRD contains a de-identified unique patient linkage number, which allows for the determination of readmissions 
by tracking of patients across hospitals within a calendar year.
We included men and women, aged 18 years or older, who underwent PCI with discharge dates between 
2010 and 2014 with 30-day follow up. The NRD contains up to 15 procedural codes for each inpatient admission. 
PCI was defined by the procedural code 066 (PTCA OR CORONARY ATHER), 3606 (INSERT CORON ART 
STENT) and 3607 (INSERT DRUG ELUTING CRNRY AR)10.
The NRD also contains International Statistical Classification of Disease and Related Health Problems 
(ICD) 9 codes, Elixhauser comorbidity codes and Clinical Classification Software (CCS) codes. The Charlson 
Comorbidity Index (CCI) is a measure of co-morbidity burden which provides a measure of the prognostic 
impact of 17 comorbid conditions which considers the number of comorbidities and their individual prognostic 
value6. We used the Elixhauser comorbidity variables and the paralysis variable from Elixhauser comorbidities 
as a surrogate for hemiplegia and the connective tissue disease and leukemia from the CCS codes 210, 211 & 39 
respectively to calculate the CCI. The continuous CCI score was then categorized into comorbidity groups with 








CCI ≥ 3 
(n = 64,185) p-value
Length of stay 3.5 ± 4.6 3.9 ± 5.1 4.5 ± 5.4 5.2 ± 6.1 <0.001
Cost $10,974 ± 16,617 $11,532 ± 16,049 $12,064 ± 16,574 $13,177 ± 17,807 <0.001
Death 1.7% 2.3% 3.0% 3.9% <0.001
Table 3. Outcomes for readmission by comorbidity group.
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CCI score of 0, 1, 2 and ≥327. Patients were excluded if they died during index PCI, discharged during the month 
of December and had a planned readmission within 30 days.
Several variables were collected in the analysis. Age, sex, year, elective admission, weekend admission, primary 
expected payer, median household income, hospital-bed number, location, teaching status, discharge location, 
length of stay, and cost were available in the NRD dataset. Diagnosis of acute myocardial infarction was defined 
as a first diagnostic code of 410*1 or 4111. Using the ICD-9 diagnostic codes we defined several patient varia-
bles including smoking status (V1582 3051), dyslipidemia (2720–2724), complete heart block (4260), stroke or 
transient ischemic attack (431 433*1 434*1 435* 4336* 99701), cardiogenic shock (78551), cardiac arrest (4275), 
acute kidney injury (4590* 56881 5789* V582* 431* 4329*) and bleeding (4590* 56881 5782* 431* 4329*). 
Vascular complications were determined by ICD-9 diagnostic codes (900–904 9982 9992 9977 86804) and ICD-9 
procedural codes (3931 3941 3949 3952 3956 3957 3959 3979). ICD-9 procedural codes were used to define 
receipt of circulatory support (3761 3768 3965), multivessel disease (0041 0042 0043 0046 0047 0048), bifurca-
tion disease (0044), vasopressor use (0017), intraaortic balloon pump use (3761), fractional flow reserve (0059), 
intravascular ultrasound (0024), drug eluting stent (3607) and blood transfusion (9900). Elixhauser comorbidity 
code was used to define alcohol misuse.
The primary outcome of the study was 30-day unplanned all-cause readmissions and the causes of readmis-
sions. The causes of readmission were defined by the first diagnosis based on the Clinical Classification Software 
codes which are shown in Supplementary Table 1.
Statistical analysis was performed on Stata 14.0 (College Station, TX). Descriptive statistics are presented 
according to comorbidity group and readmission status for all included variables. The one-way analysis of var-
iance was used to compare continuous variables while the Chi2 test was used to compare categorical variables 
according to comorbidity group. Trends in the prevalence of patients in each comorbidity group and readmis-
sion rates are shown graphically. Simple and multiple logistic regressions adjusted for all variables were used to 
identify the effect of comorbidity group on 30-day readmissions. Causes of readmission were explored in a table. 
A flow diagram was used to describe patient outcomes for both admission and readmissions. In addition, for 
the analysis of the odds of readmission by CCI score we adjusted for the baseline covariates not included in the 
CCI score which included age, sex, year, elective PCI, weekend procedure, acute myocardial infarction, primary 
expected payer, income, smoking, alcohol, dyslipidaemia, hypertension, hospital bed size, urban hospital, teach-
ing hospital, multivessel PCI, bifurcation PCI, circulatory support, vasopressor use, intra-aortic balloon pump 
use, fractional flow reserve, intravascular ultrasound, drug eluting stent, complete heart block, stroke or TIA, 
cardiac arrest, acute kidney injury, bleeding, vascular complication, emergency CABG and discharge location.
Data availability statement. The data in the current manuscript is not available.
Ethical approval and informed consent. The study is an analysis of anonymized data and ethical 
approval and informed consent was not required.
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